Skip to main content

Psoriatic arthritis

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Apr 01, 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.



Janus kinase

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2021

Psoriatic Disease Management - RNL 2021 Highlights

Mar 29, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article
Takeaways from #RNL2021 from Dr. Rachel Tate ( @uptoTate ) "Severe flares in PsO pts previously well controlled: look for infection (HIV or other) and/or underlying malignancy. Melodie Young, NP #RNL2021" #RheumNow

Dr. John Cush @RheumNow( View Tweet )

Mar 29, 2021
Our in-person participants engaging with the psoriatic panel #RNL2021 https://t.co/N0Cdos3Rhb
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2021
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Dr. John Cush @RheumNow( View Tweet )

Mar 19, 2021
SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48

Dr. John Cush @RheumNow( View Tweet )

Mar 19, 2021

RheumNow Podcast – Great Associations (3.19.2021)

Mar 18, 2021

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article

Are You a Super Rheum?

Mar 18, 2021

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective

Read Article

Apremilast Equals MTX in Palmoplantar Psoriasis

Mar 18, 2021

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Read Article
Rinvoq (upadacitinib) was slated for a psoriatic arthritis indication this month, but now that has been pushed back ~90days, pending further FDA review of the benefit-risk profile for upadacitinib in psoriatic arthritis https://t.co/FeBOrNIbTo

Dr. John Cush @RheumNow( View Tweet )

Mar 17, 2021

Enthesitis Responses to Secukinumab in Spondylitis Patients

Mar 16, 2021

Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.



Pooled data from the

Read Article

Rheumatic Patients Are at Risk for COVID Death

MedPage Today
Mar 16, 2021

Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry

Read Article
RheumNow Live starts one week from today! The 2021 RheumNow Live current speaker list includes: Roy Fleischmann, Clay Cockerell, Eric Ruderman, Alexis Ogdie, Philip Robinson, Jeff Sparks, Nigel Haroon, Artie Kavanaugh, and Jack Cush. Register today. https://t.co/Woxi4Ri0O5 https://t.co/nbm4AFXmlv
Dr. John Cush @RheumNow( View Tweet )
Mar 13, 2021

Low IBD Risk with IL-17 Inhibition

Mar 08, 2021

Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.



A real-world study of the secukinumab (SEC; an IL-17 inhibitor) and gastrointestinal related adverse events (GIRAE)

Read Article

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
Report from DANBIO Danish register looked at chronic pain in a matched cohort study of Psoriasis. Chronic pain was not associated with excess mortality (hence not PsA) (OR 0.99,0.95-1.03). Mortality was increased with steriods, COPD, DM, CA, CV disease.  https://t.co/91JW3BOPtw

Dr. John Cush @RheumNow( View Tweet )

Mar 02, 2021
News Feature: MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients https://t.co/34RU4OSaRi

Dr. John Cush @RheumNow( View Tweet )

Feb 28, 2021

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Feb 26, 2021

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
×